Current Data
We will be updating our data biweekly as new reports continue to come in.
Last Updated: 05/15/2020
Total Number of Cases Reported: 35
Cases Reported by State (U.S. only)*
| State | Reported Cases |
|---|---|
| ARIZONA | 2 |
| CALIFORNIA | 7 |
| CONNECTICUT | 3 |
| INDIANA | 1 |
| PENNSYLVANIA | 1 |
| MASSACHUSETTS | 2 |
| TEXAS | 1 |
| MARYLAND | 10 |
*States not included in this table have not reported any cases to CURE HIV-COVID
Cases and Outcomes by Patient Characteristics
| Characteristic | TOTAL Number | % Hospitalized | Supportive Care (no supplemental O2) in Hospital | Supplemental O2 | High Flow O2 | Mechanical Ventilator | ECMO | Resolved | Symtomatic not Hospitalized | Symptomatic Remains Hospitalized | Deceased |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | 35 | 34% | 20% | 20% | 0% | 60% | 33% | 53% | 18% | 18% | 12% |
| Age | |||||||||||
| 18-29 years | |||||||||||
| 30-39 years | 7 | 0% | 0% | 0% | 0% | 0% | 0% | 100% | 0% | 0% | 0% |
| 40-49 years | 11 | 36% | 50% | 25% | 0% | 25% | 0% | 55% | 27% | 0% | 9% |
| 50-59 years | 10 | 40% | 25% | 25% | 0% | 50% | 0% | 60% | 10% | 20% | 0% |
| 60-69 years | 4 | 50% | 0% | 0% | 0% | 50% | 0% | 25% | 25% | 50% | 0% |
| 70-79 years | 1 | 0% | 0% | 0% | 0% | 0% | 0% | 100% | 0% | 0% | 0% |
| >=80 years | 2 | 100% | 0% | 0% | 0% | 100% | 0% | 0% | 0% | 0% | 100% |
| Sex | |||||||||||
| Male | 24 | 33% | 33% | 14% | 0% | 43% | 0% | 63% | 17% | 4% | 13% |
| Female | 10 | 40% | 40% | 25% | 0% | 50% | 0% | 60% | 0% | 30% | 0% |
| Male-to-Female Trans | 1 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 100% | 0% | 0% |
| Race | |||||||||||
| Arab | |||||||||||
| Black | 16 | 44% | 29% | 0% | 0% | 57% | 0% | 50% | 6% | 25% | 6% |
| East Asian | |||||||||||
| South Asian | |||||||||||
| West Asian | |||||||||||
| Middle Eastern | |||||||||||
| Pacific Islander | 1 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 100% | 0% | 0% |
| Latin American | |||||||||||
| Caucasian | 14 | 36% | 25% | 50% | 0% | 25% | 0% | 72% | 14% | 0% | 14% |
| Native American | |||||||||||
| Aboriginal | |||||||||||
| First Nations | |||||||||||
| Other | 3 | 33% | 67% | 23% | 0% | 0% | 0% | 67% | 23% | 0% | 0% |
| Unknown | 1 | 100% | 0% | 0% | 0% | 100% | 0% | 100% | 0% | 0% | 0% |
| Average CD4 Count | 460 Hosp. vs 648 Not Hosp | ||||||||||
| % CD4 Pre-Covid/During Covid/Not Available | 94/0/6 | ||||||||||
| Average HIV VL | 107 Hosp vs <20 Not Hosp | ||||||||||
| % HI VL Pre-Covid/During Covid/Not Available | 94/0/6 | ||||||||||
| AIDS | 13 | 38% | 20% | 20% | 0% | 60% | 0% | 69% | 8% | 15% | 8% |
| Never Met AIDS Criteria | 7 | 2% | 33% | 33% | 0% | 0% | 33% | 56% | 19% | 6% | 6% |
| Not Known | 2 | 50% | 0% | 0% | 0% | 40% | 0% | 50% | 0% | 0% | 50% |
| COVID Treatment | |||||||||||
| Remdesivir | |||||||||||
| Lopinavir/ritonavir | |||||||||||
| Chloroquine | |||||||||||
| Hydroxychloroquine | 6 | 67% | 0% | 33% | 0% | 67% | 0% | 62% | 14% | 10% | 7% |
| Hydroxychloroquine + Azithromycin | 3 | 0% | 0% | 0% | 0% | 0% | 0% | 33% | 33% | 0% | 33% |
| Azithromycin | 6 | 50% | 0% | 0% | 0% | 100% | 0% | 33% | 17% | 33% | 17% |
| IL-6 inhibitors | |||||||||||
| Bevacizumab | |||||||||||
| JAK inhibitor | |||||||||||
| Serpin inhibitor | |||||||||||
| Ciclesonide | |||||||||||
| Glucocorticoids (including if given for any complications) | 3 | 100% | 0% | 33% | 0% | 67% | 0% | 33% | 9% | 33% | 33% |
| IVIG | |||||||||||
| Plasma from recovered patients | |||||||||||
| Therapeutic Anticogulation | |||||||||||
| None | 22 | 9% | 50% | 50% | 0% | 0% | 0% | 75% | 13% | 6% | 0% |
| Unknown | 1 | 100% | 0% | 0% | 0% | 100% | 0% | 0% | 0% | 0% | 100% |
| Other |